We know, Ofirmev is a great product, cash cow. Now, management is doing all right moves!
Will brake 7.50-8.0 resistance in short order.
From this point going only in one direction, up.
Acute pain therapy is bullet and recession proof product.
- money coming in, and cutting cost, looks like they let go a few reps ( thank you, I got my wish: more money less cost )
- margins up and will stay north of 60%
- looking at new product, but not rushing in
- coming to Canada soon ( I can see Ofirmev used for almost all ortho cases and laparoscopic surgery at my place )
- adding more money in the bank ( no dilution unless some major acquisition )
- new accounts, plus increasing number vials per patient
- very respectable guidance ( I have feeling management underestimating and numbers will be a "surprise" )
- they feel very strong about IP, generics are not an issue, most likely settlement before court date...
- unprofessional Baxter is out, no more supply/manufacturing distractions, building new plant with Baxter is off the table
- very likely buyout target once they are north of 100M and positive cash flow
- we will have very soon published reports in med journals and increase visibility at all pain meetings/conferences
Agree, still not time for any acquisition, unless something comes out as super quality for discounted price. They did bail out very well from Incline, got out and even made profit. CC, they said not rushing into anything, just looking.....